VET3-TGI + pembrolizumab

VET3-TGI + pembrolizumab is a **combination therapy** composed of VET3-TGI, a novel veterinary immunotherapy candidate, and pembrolizumab, a human monoclonal antibody immune checkpoint inhibitor targeting PD-1. Pembrolizumab is approved for multiple cancers in humans but is not used routinely in veterinary medicine due to species specificity; instead alternatives such as gilvetmab are used in dogs[2][5]. VET3-TGI is presumed to be an investigational veterinary immune therapy, but there is no publicly indexed information describing its molecular modality, mechanism, or trial status in combination with pembrolizumab or otherwise as of September 2025. Pembrolizumab functions by blocking the PD-1 receptor on T cells, thereby enhancing immune-mediated anti-tumor response. The intent of combining these agents is to harness complementary or additive immunomodulatory effects, but the specifics for this combination in veterinary or human medicine are not established in the literature[2].

Other names

VET3-TGIVET-3-TGIVET 3-TGIpembrolizumab